Please login to the form below

Not currently logged in
Email:
Password:

HER2-positive non-small cell lung cancer

This page shows the latest HER2-positive non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small

Latest news

  • Roche's Kadcyla fails in gastric cancer trial Roche's Kadcyla fails in gastric cancer trial

    The trial is particularly disappointing as Kadcyla parent Herceptin has previously been shown to be effective in HER2-positive gastric cancer, and has been approved for this use for several years. ... expand its use into early breast cancer and is also

  • Avastin approved for cervical cancer in EU Avastin approved for cervical cancer in EU

    Roche's Avastin has added to its long list of approved indications with a green light in the EU to treat cervical cancer. . ... It is also in trials for additional indications including adjuvant treatment of HER2-positive and HER2-negative breast cancer

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....